Purinergic system in cancer stem cells.
Cancer stem cells
Ectonucleotidases
Epithelial to mesenchymal transition
Purinergic receptors
Purinergic signaling in cancer
Journal
Purinergic signalling
ISSN: 1573-9546
Titre abrégé: Purinergic Signal
Pays: Netherlands
ID NLM: 101250499
Informations de publication
Date de publication:
15 Nov 2023
15 Nov 2023
Historique:
received:
10
06
2023
accepted:
25
10
2023
medline:
15
11
2023
pubmed:
15
11
2023
entrez:
15
11
2023
Statut:
aheadofprint
Résumé
Accumulating evidence supports the idea that cancer stem cells (CSCs) are those with the capacity to initiate tumors, generate phenotypical diversity, sustain growth, confer drug resistance, and orchestrate the spread of tumor cells. It is still controversial whether CSCs originate from normal stem cells residing in the tissue or cancer cells from the tumor bulk that have dedifferentiated to acquire stem-like characteristics. Although CSCs have been pointed out as key drivers in cancer, knowledge regarding their physiology is still blurry; thus, research focusing on CSCs is essential to designing novel and more effective therapeutics. The purinergic system has emerged as an important autocrine-paracrine messenger system with a prominent role at multiple levels of the tumor microenvironment, where it regulates cellular aspects of the tumors themselves and the stromal and immune systems. Recent findings have shown that purinergic signaling also participates in regulating the CSC phenotype. Here, we discuss updated information regarding CSCs in the purinergic system and present evidence supporting the idea that elements of the purinergic system expressed by this subpopulation of the tumor represent attractive pharmacological targets for proposing innovative anti-cancer therapies.
Identifiants
pubmed: 37966629
doi: 10.1007/s11302-023-09976-5
pii: 10.1007/s11302-023-09976-5
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : PAPIIT-UNAM
ID : IN205223
Organisme : PAPIIT-UNAM
ID : IN205223
Organisme : PAPIIT-UNAM
ID : IN205223
Organisme : FAPESP-Brazil
ID : 2022/11093-9
Organisme : FAPESP-Brazil
ID : 2022/11093-9
Informations de copyright
© 2023. The Author(s).
Références
Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer . Accessed 13 Mar 2023
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674. https://doi.org/10.1016/J.CELL.2011.02.013
doi: 10.1016/J.CELL.2011.02.013
pubmed: 21376230
Huntly BJP, Gilliland DG (2005) Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat Rev Cancer 5:311–321. https://doi.org/10.1038/NRC1592
doi: 10.1038/NRC1592
pubmed: 15803157
Teng YD, Wang L, Kabatas S et al (2018) Cancer stem cells or tumor survival cells? Stem Cells Dev 27:1466–1478. https://doi.org/10.1089/scd.2018.0129
doi: 10.1089/scd.2018.0129
pubmed: 30092726
Yoo YD, Kwon YT (2015) Molecular mechanisms controlling asymmetric and symmetric self-renewal of cancer stem cells. J Anal Sci Technol 6. https://doi.org/10.1186/S40543-015-0071-4
Vermeulen L, Sprick MR, Kemper K et al (2008) Cancer stem cells - old concepts, new insights. Cell Death Differ 15:947–958. https://doi.org/10.1038/cdd.2008.20
doi: 10.1038/cdd.2008.20
pubmed: 18259194
Kuşoğlu A, Biray Avcı Ç (2019) Cancer stem cells: a brief review of the current status. Gene 681:80–85. https://doi.org/10.1016/J.GENE.2018.09.052
doi: 10.1016/J.GENE.2018.09.052
pubmed: 30268439
Bonnet D, Dick JE (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3:730–737. https://doi.org/10.1038/NM0797-730
doi: 10.1038/NM0797-730
Al-Hajj M, Wicha MS, Benito-Hernandez A et al (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100:3983–3988. https://doi.org/10.1073/PNAS.0530291100
doi: 10.1073/PNAS.0530291100
pubmed: 12629218
pmcid: 153034
Singh SK, Clarke ID, Hide T, Dirks PB (2004) Cancer stem cells in nervous system tumors. Oncogene 23:7267–7273. https://doi.org/10.1038/sj.onc.1207946
doi: 10.1038/sj.onc.1207946
pubmed: 15378086
Szotek PP, Pieretti-Vanmarcke R, Masiakos PT et al (2006) Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian inhibiting substance responsiveness. Proc Natl Acad Sci U S A 103:11154–11159. https://doi.org/10.1073/PNAS.0603672103
doi: 10.1073/PNAS.0603672103
pubmed: 16849428
pmcid: 1544057
Collins AT, Berry PA, Hyde C et al (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65:10946–10951. https://doi.org/10.1158/0008-5472.CAN-05-2018
doi: 10.1158/0008-5472.CAN-05-2018
pubmed: 16322242
Li C, Heidt DG, Dalerba P et al (2007) Identification of pancreatic cancer stem cells. Cancer Res 67:1030–1037. https://doi.org/10.1158/0008-5472.CAN-06-2030
doi: 10.1158/0008-5472.CAN-06-2030
pubmed: 17283135
Eramo A, Lotti F, Sette G et al (2008) Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 15:504–514. https://doi.org/10.1038/SJ.CDD.4402283
doi: 10.1038/SJ.CDD.4402283
Hermann PC, Huber SL, Herrler T et al (2007) Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1:313–323. https://doi.org/10.1016/J.STEM.2007.06.002
doi: 10.1016/J.STEM.2007.06.002
pubmed: 18371365
Prince ME, Sivanandan R, Kaczorowski A et al (2007) Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A 104:973–978. https://doi.org/10.1073/PNAS.0610117104
doi: 10.1073/PNAS.0610117104
pubmed: 17210912
pmcid: 1783424
O’Brien CA, Pollett A, Gallinger S, Dick JE (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445:106–110. https://doi.org/10.1038/NATURE05372
doi: 10.1038/NATURE05372
pubmed: 17122772
Ailles LE, Weissman IL (2007) Cancer stem cells in solid tumors. Curr Opin Biotechnol 18:460–466. https://doi.org/10.1016/J.COPBIO.2007.10.007
doi: 10.1016/J.COPBIO.2007.10.007
pubmed: 18023337
Leedham S, Schier S, Thliveris AT et al (2005) From gene mutations to tumours–stem cells in gastrointestinal carcinogenesis. Cell Prolif 38:387–405. https://doi.org/10.1111/J.1365-2184.2005.00359.X
doi: 10.1111/J.1365-2184.2005.00359.X
pubmed: 16300652
pmcid: 6496903
White AC, Lowry WE (2015) Refining the role for adult stem cells as cancer cells of origin. Trends Cell Biol 25:11–20. https://doi.org/10.1016/J.TCB.2014.08.008
doi: 10.1016/J.TCB.2014.08.008
pubmed: 25242116
Ayob AZ, Ramasamy TS (2018) Cancer stem cells as key drivers of tumour progression. J Biomed Sci 25. https://doi.org/10.1186/S12929-018-0426-4
Bergsmedh A, Szeles A, Henriksson M et al (2001) Horizontal transfer of oncogenes by uptake of apoptotic bodies. Proc Natl Acad Sci U S A 98:6407–6411. https://doi.org/10.1073/PNAS.101129998
doi: 10.1073/PNAS.101129998
pubmed: 11353826
pmcid: 33481
Atashzar MR, Baharlou R, Karami J et al (2020) Cancer stem cells: a review from origin to therapeutic implications. J Cell Physiol 235:790–803. https://doi.org/10.1002/JCP.29044
doi: 10.1002/JCP.29044
pubmed: 31286518
Schofield R (1978) The relationship between the spleen colony-forming cell and the haemopoietic stem cell. Blood Cells 4:7–25
pubmed: 747780
Ferraro F, Lo Celso C, Scadden D (2010) Adult stem cels and their niches. Adv Exp Med Biol 695:155–168. https://doi.org/10.1007/978-1-4419-7037-4_11
doi: 10.1007/978-1-4419-7037-4_11
pmcid: 4020242
Anderson NM, Simon MC (2020) The tumor microenvironment. Curr Biol 30:R921–R925. https://doi.org/10.1016/J.CUB.2020.06.081
doi: 10.1016/J.CUB.2020.06.081
pubmed: 32810447
pmcid: 8194051
Plaks V, Kong N, Werb Z (2015) The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells? Cell Stem Cell 16:225–238. https://doi.org/10.1016/J.STEM.2015.02.015
doi: 10.1016/J.STEM.2015.02.015
pubmed: 25748930
pmcid: 4355577
Motohara T, Yoshida GJ, Katabuchi H (2021) The hallmarks of ovarian cancer stem cells and niches: exploring their harmonious interplay in therapy resistance. Semin Cancer Biol 77:182–193. https://doi.org/10.1016/J.SEMCANCER.2021.03.038
doi: 10.1016/J.SEMCANCER.2021.03.038
pubmed: 33812986
Qin X, Yan M, Zhang J et al (2016) TGFβ3-mediated induction of periostin facilitates head and neck cancer growth and is associated with metastasis. Sci Rep 6. https://doi.org/10.1038/SREP20587
Kuperwasser C, Chavarria T, Wu M et al (2004) Reconstruction of functionally normal and malignant human breast tissues in mice. Proc Natl Acad Sci U S A 101:4966–4971. https://doi.org/10.1073/PNAS.0401064101
doi: 10.1073/PNAS.0401064101
pubmed: 15051869
pmcid: 387357
Zhao R, Bei X, Yang B et al (2018) Endothelial cells promote metastasis of prostate cancer by enhancing autophagy. J Exp Clin Cancer Res 37. https://doi.org/10.1186/S13046-018-0884-2
Raghavan S, Mehta P, Xie Y et al (2019) Ovarian cancer stem cells and macrophages reciprocally interact through the WNT pathway to promote pro-tumoral and malignant phenotypes in 3D engineered microenvironments. J Immunother Cancer 7. https://doi.org/10.1186/S40425-019-0666-1
Lu P, Weaver VM, Werb Z (2012) The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol 196:395–406. https://doi.org/10.1083/JCB.201102147
doi: 10.1083/JCB.201102147
pubmed: 22351925
Bourguignon LYW, Peyrollier K, Xia W, Gilad E (2008) Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. J Biol Chem 283:17635–17651. https://doi.org/10.1074/JBC.M800109200
doi: 10.1074/JBC.M800109200
pubmed: 18441325
pmcid: 2427357
Ehata S, Johansson E, Katayama R et al (2011) Transforming growth factor-β decreases the cancer-initiating cell population within diffuse-type gastric carcinoma cells. Oncogene 30:1693–1705. https://doi.org/10.1038/ONC.2010.546
doi: 10.1038/ONC.2010.546
pubmed: 21132002
Bellomo C, Caja L, Moustakas A (2016) Transforming growth factor β as regulator of cancer stemness and metastasis. Br J Cancer 115:761–769. https://doi.org/10.1038/BJC.2016.255
doi: 10.1038/BJC.2016.255
pubmed: 27537386
pmcid: 5046208
Feng Y, Dai X, Li X et al (2012) EGF signalling pathway regulates colon cancer stem cell proliferation and apoptosis. Cell Prolif 45:413–419. https://doi.org/10.1111/J.1365-2184.2012.00837.X
doi: 10.1111/J.1365-2184.2012.00837.X
pubmed: 22925500
pmcid: 6495284
Sheta M, Hassan G, Afify SM et al (2021) Chronic exposure to FGF2 converts iPSCs into cancer stem cells with an enhanced integrin/focal adhesion/PI3K/AKT axis. Cancer Lett 521:142–154. https://doi.org/10.1016/J.CANLET.2021.08.026
doi: 10.1016/J.CANLET.2021.08.026
pubmed: 34455015
Pellegatti P, Raffaghello L, Bianchi G et al (2008) Increased level of extracellular ATP at tumor sites: in vivo imaging with plasma membrane luciferase. PLoS One 3. https://doi.org/10.1371/JOURNAL.PONE.0002599
Feng LL, Cai YQ, Zhu MC et al (2020) The yin and yang functions of extracellular ATP and adenosine in tumor immunity. Cancer Cell Int 20. https://doi.org/10.1186/S12935-020-01195-X
Lecciso M, Ocadlikova D, Sangaletti S et al (2017) ATP release from chemotherapy-treated dying leukemia cells elicits an immune suppressive effect by increasing regulatory T cells and tolerogenic dendritic cells. Front Immunol 8. https://doi.org/10.3389/FIMMU.2017.01918
Raczyńska ED, Makowski M (2014) Geometric consequences of electron delocalization for adenine tautomers in aqueous solution. J Mol Model 20. https://doi.org/10.1007/S00894-014-2234-4
Martins Z (2018) The nitrogen heterocycle content of meteorites and their significance for the origin of life. Life 8. https://doi.org/10.3390/LIFE8030028 . (Basel, Switzerland)
Kitadai N, Maruyama S (2018) Origins of building blocks of life: a review. Geosci Front 9:1117–1153. https://doi.org/10.1016/J.GSF.2017.07.007
doi: 10.1016/J.GSF.2017.07.007
Enchev V, Angelov I, Dincheva I et al (2021) Chemical evolution: from formamide to nucleobases and amino acids without the presence of catalyst. J Biomol Struct Dyn 39:1–16. https://doi.org/10.1080/07391102.2020.1792986
doi: 10.1080/07391102.2020.1792986
Cysewski P (2005) An ab initio DFT characteristics of tautomeric properties of hydroxyl radical modified nucleosides in polar and non-polar environments. Zeitschrift Phys Chemie 219:213–234. https://doi.org/10.1524/ZPCH.219.2.213.57306/MACHINEREADABLECITATION/RIS
doi: 10.1524/ZPCH.219.2.213.57306/MACHINEREADABLECITATION/RIS
Butanda-Ochoa A, Höjer G, Díaz-Muñoz M (2003) Modulation of the skeletal muscle Ca2+ release channel/ryanodine receptor by adenosine and its metabolites: a structure-activity approach. Bioorganic Med Chem 11:3029–3037. https://doi.org/10.1016/S0968-0896(03)00155-X
doi: 10.1016/S0968-0896(03)00155-X
Butanda-Ochoa A, Hojer G, Morales-Tlalpan V, Diaz-Munoz M (2006) Recognition and activation of ryanodine receptors by purines. Curr Med Chem 13:647–657. https://doi.org/10.2174/092986706776055715
doi: 10.2174/092986706776055715
pubmed: 16529557
Buelens FP, Leonov H, De Groot BL, Grubmüller H (2021) ATP-magnesium coordination: protein structure-based force field evaluation and corrections. J Chem Theory Comput 17:1922–1930. https://doi.org/10.1021/ACS.JCTC.0C01205
doi: 10.1021/ACS.JCTC.0C01205
pubmed: 33616388
pmcid: 8023659
Kobayashi E, Yura K, Nagai Y (2013) Distinct conformation of ATP molecule in solution and on protein. Biophys 9:1–12. https://doi.org/10.2142/BIOPHYSICS.9.1 . (Nagoya-shi, Japan)
doi: 10.2142/BIOPHYSICS.9.1
Jacobson K, Costanzi S, Ohno M et al (2004) Molecular recognition at purine and pyrimidine nucleotide (P2) receptors. Curr Top Med Chem 4:805–819. https://doi.org/10.2174/1568026043450961
doi: 10.2174/1568026043450961
pubmed: 15078212
pmcid: 4428617
Pareek V, Pedley AM, Benkovic SJ (2021) Human de novo purine biosynthesis. Crit Rev Biochem Mol Biol 56:1–16. https://doi.org/10.1080/10409238.2020.1832438
doi: 10.1080/10409238.2020.1832438
pubmed: 33179964
de Sánchez VC, Hernández-Muñoz R, Díaz-Muñoz M et al (1983) Circadian variations of adenosine level in blood and liver and its possible physiological significance. Life Sci 33:1057–1064. https://doi.org/10.1016/0024-3205(83)90661-6
doi: 10.1016/0024-3205(83)90661-6
Atkinson DE, Walton GM (1967) Adenosine triphosphate conservation in metabolic regulation. J Biol Chem 242:3239–3241. https://doi.org/10.1016/s0021-9258(18)95956-9
doi: 10.1016/s0021-9258(18)95956-9
pubmed: 6027798
Lin SC, Hardie DG (2018) AMPK: sensing glucose as well as cellular energy status. Cell Metab 27:299–313. https://doi.org/10.1016/J.CMET.2017.10.009
doi: 10.1016/J.CMET.2017.10.009
pubmed: 29153408
Chagoya de Sánchez V, Brunner A, Piña E (1972) In vivo modification of the energy charge in the liver cell. Biochem Biophys Res Commun 46:1441–1445. https://doi.org/10.1016/S0006-291X(72)80138-4
doi: 10.1016/S0006-291X(72)80138-4
pubmed: 5012180
Pasalic D, Marinkovic N, Feher-Turkovic L (2012) Uric acid as one of the important factors in multifactorial disorders--facts and controversies. Biochem Med 22:63–75. https://doi.org/10.11613/BM.2012.007
doi: 10.11613/BM.2012.007
Chung HY, Baek BS, Song SH et al (1997) Xanthine dehydrogenase/xanthine oxidase and oxidative stress. Age 20:127–140. https://doi.org/10.1007/S11357-997-0012-2 . (Omaha)
doi: 10.1007/S11357-997-0012-2
pubmed: 23604305
pmcid: 3455892
Su X, Wellen KE, Rabinowitz JD (2016) Metabolic control of methylation and acetylation. Curr Opin Chem Biol 30:52–60. https://doi.org/10.1016/J.CBPA.2015.10.030
doi: 10.1016/J.CBPA.2015.10.030
pubmed: 26629854
Drury AN, Szent-Györgyi A (1929) The physiological activity of adenine compounds with especial reference to their action upon the mammalian heart. J Physiol 68:213–237. https://doi.org/10.1113/JPHYSIOL.1929.SP002608
doi: 10.1113/JPHYSIOL.1929.SP002608
pmcid: 1402863
Burnstock G (1972) Purinergic nerves. Pharmacol Rev 24:509–581
Huang Z, Xie N, Illes P et al (2021) From purines to purinergic signalling: molecular functions and human diseases. Signal Transduct Target Ther 6. https://doi.org/10.1038/S41392-021-00553-Z
Coddou C, Yan Z, Obsil T et al (2011) Activation and regulation of purinergic P2X receptor channels. Pharmacol Rev 63:641–683. https://doi.org/10.1124/PR.110.003129
doi: 10.1124/PR.110.003129
pubmed: 21737531
pmcid: 3141880
Ralevic V, Burnstock G (1998) Receptors for purines and pyrimidines. Pharmacol Rev 50:413–492. https://doi.org/10.1007/978-3-642-28863-0_5
doi: 10.1007/978-3-642-28863-0_5
pubmed: 9755289
Faas MM, Sáez T, de Vos P (2017) Extracellular ATP and adenosine: the Yin and Yang in immune responses? Mol Aspects Med 55:9–19. https://doi.org/10.1016/j.mam.2017.01.002
doi: 10.1016/j.mam.2017.01.002
pubmed: 28093236
Haulicǎ I, Ababei L, Brǎnişlteanu D, Topoliceanu F (1973) Letter: preliminary data on the possible hypnogenic role of adenosine. J Neurochem 21:1019–1020. https://doi.org/10.1111/J.1471-4159.1973.TB07549.X
doi: 10.1111/J.1471-4159.1973.TB07549.X
pubmed: 4754851
García-Baizán A, Millor M, Bartolomé P et al (2019) Adenosine triphosphate (ATP) and adenosine cause similar vasodilator effect in patients undergoing stress perfusion cardiac magnetic resonance imaging. Int J Cardiovasc Imaging 35:675–682. https://doi.org/10.1007/S10554-018-1494-Y
doi: 10.1007/S10554-018-1494-Y
pubmed: 30426300
Andrejew R, Glaser T, Oliveira-Giacomelli Á et al (2019) Targeting purinergic signaling and cell therapy in cardiovascular and neurodegenerative diseases. Adv Exp Med Biol 1201:275–353. https://doi.org/10.1007/978-3-030-31206-0_14
doi: 10.1007/978-3-030-31206-0_14
pubmed: 31898792
Ribeiro DE, Petiz LL, Glaser T et al (2023) Purinergic signaling in cognitive impairment and neuropsychiatric symptoms of Alzheimer’s disease. Neuropharmacology 226. https://doi.org/10.1016/J.NEUROPHARM.2022.109371
Campos-Contreras ADR, Díaz-Muñoz M, Vázquez-Cuevas FG (2020) Purinergic signaling in the hallmarks of cancer. Cells 9. https://doi.org/10.3390/CELLS9071612
Alvarez CL, Troncoso MF, Espelt MV (2022) Extracellular ATP and adenosine in tumor microenvironment: roles in epithelial-mesenchymal transition, cell migration, and invasion. J Cell Physiol 237:389–400. https://doi.org/10.1002/JCP.30580
doi: 10.1002/JCP.30580
pubmed: 34514618
Vultaggio-Poma V, Sarti AC, Di Virgilio F (2020) Extracellular ATP: a feasible target for cancer therapy. Cells 9:1–22. https://doi.org/10.3390/CELLS9112496
doi: 10.3390/CELLS9112496
Kepp O, Bezu L, Yamazaki T et al (2021) ATP and cancer immunosurveillance. EMBO J 40. https://doi.org/10.15252/EMBJ.2021108130
Nakajima EC, Van Houten B (2013) Metabolic symbiosis in cancer: refocusing the Warburg lens. Mol Carcinog 52:329–337. https://doi.org/10.1002/MC.21863
doi: 10.1002/MC.21863
pubmed: 22228080
Reyna-Jeldes M, Díaz-Muñoz M, Madariaga JA et al (2021) Autocrine and paracrine purinergic signaling in the most lethal types of cancer. Purinergic Signal 17:345–370. https://doi.org/10.1007/S11302-021-09785-8
doi: 10.1007/S11302-021-09785-8
pubmed: 33982134
pmcid: 8410929
Solini A, Cuccato S, Ferrari D et al (2008) Increased P2X7 receptor expression and function in thyroid papillary cancer: a new potential marker of the disease? Endocrinology 149:389–396. https://doi.org/10.1210/EN.2007-1223
doi: 10.1210/EN.2007-1223
pubmed: 17947359
Adinolfi E, Raffaghello L, Giuliani AL et al (2012) Expression of P2X7 receptor increases in vivo tumor growth. Cancer Res 72:2957–2969. https://doi.org/10.1158/0008-5472.CAN-11-1947
doi: 10.1158/0008-5472.CAN-11-1947
pubmed: 22505653
Amoroso F, Capece M, Rotondo A et al (2015) The P2X7 receptor is a key modulator of the PI3K/GSK3β/VEGF signaling network: evidence in experimental neuroblastoma. Oncogene 34:5240–5251. https://doi.org/10.1038/ONC.2014.444
doi: 10.1038/ONC.2014.444
pubmed: 25619831
Vázquez-Cuevas FG, Martínez-Ramírez AS, Robles-Martínez L et al (2014) Paracrine stimulation of P2X7 receptor by ATP activates a proliferative pathway in ovarian carcinoma cells. J Cell Biochem 115:1955–1966. https://doi.org/10.1002/JCB.24867
doi: 10.1002/JCB.24867
pubmed: 24913779
Haas CB, Lovászi M, Braganhol E et al (2021) Ectonucleotidases in inflammation, immunity, and cancer. J Immunol 206:1983–1990. https://doi.org/10.4049/JIMMUNOL.2001342
doi: 10.4049/JIMMUNOL.2001342
pubmed: 33879578
Ruiz-Fernández de Córdoba B, Martínez-Monge R, Lecanda F (2023) ENPP1 immunobiology as a therapeutic target. Clin Cancer Res OF1–OF10. https://doi.org/10.1158/1078-0432.CCR-22-1681
Cappellari AR, Pillat MM, Souza HDN et al (2015) Ecto-5’-nucleotidase overexpression reduces tumor growth in a xenograph medulloblastoma model. PLoS One 10. https://doi.org/10.1371/JOURNAL.PONE.0140996
Allard B, Beavis PA, Darcy PK, Stagg J (2016) Immunosuppressive activities of adenosine in cancer. Curr Opin Pharmacol 29:7–16. https://doi.org/10.1016/J.COPH.2016.04.001
doi: 10.1016/J.COPH.2016.04.001
pubmed: 27209048
Mello P de A, Coutinho-Silva R, Savio LEB (2017) Multifaceted effects of extracellular adenosine triphosphate and adenosine in the tumor-host interaction and therapeutic perspectives. Front Immunol 8. https://doi.org/10.3389/FIMMU.2017.01526
Di Virgilio F, Vultaggio-Poma V, Falzoni S, Giuliani AL (2023) Extracellular ATP: a powerful inflammatory mediator in the central nervous system. Neuropharmacology 224. https://doi.org/10.1016/J.NEUROPHARM.2022.109333
Elliott MR, Chekeni FB, Trampont PC et al (2009) Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 461:282–286. https://doi.org/10.1038/NATURE08296
doi: 10.1038/NATURE08296
pubmed: 19741708
pmcid: 2851546
Trautmann A (2009) Extracellular ATP in the immune system: more than just a “danger signal.” Sci Signal 2. https://doi.org/10.1126/SCISIGNAL.256PE6
Ghiringhelli F, Apetoh L, Tesniere A et al (2009) Activation of the NLRP3 inflammasome in dendritic cells induces IL-1Β-dependent adaptive immunity against tumors. Nat Med 15:1170–1178. https://doi.org/10.1038/nm.2028
doi: 10.1038/nm.2028
pubmed: 19767732
Aymeric L, Apetoh L, Ghiringhelli F et al (2010) Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity. Cancer Res 70:855–858. https://doi.org/10.1158/0008-5472.CAN-09-3566
doi: 10.1158/0008-5472.CAN-09-3566
pubmed: 20086177
Aramini B, Masciale V, Grisendi G et al (2021) Cancer stem cells and macrophages: molecular connections and future perspectives against cancer. Oncotarget 12:230–250. https://doi.org/10.18632/ONCOTARGET.27870
doi: 10.18632/ONCOTARGET.27870
pubmed: 33613850
pmcid: 7869576
Arnaud-Sampaio VF, Rabelo ILA, Bento CA et al (2020) Using cytometry for investigation of purinergic signaling in tumor-associated macrophages. Cytometry A 97:1109–1126. https://doi.org/10.1002/CYTO.A.24035
doi: 10.1002/CYTO.A.24035
pubmed: 32633884
Ohta A, Gorelik E, Prasad SJ et al (2006) A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci U S A 103:13132–13137. https://doi.org/10.1073/PNAS.0605251103
doi: 10.1073/PNAS.0605251103
pubmed: 16916931
pmcid: 1559765
Deaglio S, Dwyer KM, Gao W et al (2007) Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 204:1257–1265. https://doi.org/10.1084/JEM.20062512
doi: 10.1084/JEM.20062512
pubmed: 17502665
pmcid: 2118603
Ma SR, Deng WW, Liu JF et al (2017) Blockade of adenosine A2A receptor enhances CD8+ T cells response and decreases regulatory T cells in head and neck squamous cell carcinoma. Mol Cancer 16. https://doi.org/10.1186/S12943-017-0665-0
Zarek PE, Huang CT, Lutz ER et al (2008) A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood 111:251–259. https://doi.org/10.1182/BLOOD-2007-03-081646
doi: 10.1182/BLOOD-2007-03-081646
pubmed: 17909080
Erdmann AA, Gao ZG, Jung U et al (2005) Activation of Th1 and Tc1 cell adenosine A2A receptors directly inhibits IL-2 secretion in vitro and IL-2-driven expansion in vivo. Blood 105:4707–4714. https://doi.org/10.1182/BLOOD-2004-04-1407
doi: 10.1182/BLOOD-2004-04-1407
pubmed: 15746085
pmcid: 1895001
Csóka B, Himer L, Selmeczy Z et al (2008) Adenosine A2A receptor activation inhibits T helper 1 and T helper 2 cell development and effector function. FASEB J 22:3491–3499. https://doi.org/10.1096/FJ.08-107458
doi: 10.1096/FJ.08-107458
pubmed: 18625677
pmcid: 2537430
Young A, Ngiow SF, Gao Y et al (2018) A2AR adenosine signaling suppresses natural killer cell maturation in the tumor microenvironment. Cancer Res 78:1003–1016. https://doi.org/10.1158/0008-5472.CAN-17-2826
doi: 10.1158/0008-5472.CAN-17-2826
pubmed: 29229601
Neo SY, Yang Y, Record J et al (2020) CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment. J Clin Invest 130:1185–1198. https://doi.org/10.1172/JCI128895
doi: 10.1172/JCI128895
pubmed: 31770109
pmcid: 7269592
Montalbán del Barrio I, Penski C, Schlahsa L et al (2016) Adenosine-generating ovarian cancer cells attract myeloid cells which differentiate into adenosine-generating tumor associated macrophages - a self-amplifying, CD39- and CD73-dependent mechanism for tumor immune escape. J Immunother Cancer 4. https://doi.org/10.1186/S40425-016-0154-9
Kreckler LM, Wan TC, Ge ZD, Auchampach JA (2006) Adenosine inhibits tumor necrosis factor-alpha release from mouse peritoneal macrophages via A2A and A2B but not the A3 adenosine receptor. J Pharmacol Exp Ther 317:172–180. https://doi.org/10.1124/JPET.105.096016
doi: 10.1124/JPET.105.096016
pubmed: 16339914
d’Almeida SM, Kauffenstein G, Roy C et al (2016) The ecto-ATPDase CD39 is involved in the acquisition of the immunoregulatory phenotype by M-CSF-macrophages and ovarian cancer tumor-associated macrophages: regulatory role of IL-27. Oncoimmunology 5. https://doi.org/10.1080/2162402X.2016.1178025
Bradford MD, Soltoff SP (2002) P2X7 receptors activate protein kinase D and p42/p44 mitogen-activated protein kinase (MAPK) downstream of protein kinase C. Biochem J 366:745–755. https://doi.org/10.1042/BJ20020358
doi: 10.1042/BJ20020358
pubmed: 12057008
pmcid: 1222820
Stefano L, Rössler OG, Griesemer D et al (2007) P2X(7) receptor stimulation upregulates Egr-1 biosynthesis involving a cytosolic Ca(2+) rise, transactivation of the EGF receptor and phosphorylation of ERK and Elk-1. J Cell Physiol 213:36–44. https://doi.org/10.1002/JCP.21085
doi: 10.1002/JCP.21085
pubmed: 17474086
Choi JH, Ji YG, Ko JJ et al (2018) Activating P2X7 receptors increases proliferation of human pancreatic cancer cells via ERK1/2 and JNK. Pancreas 47:643–651. https://doi.org/10.1097/MPA.0000000000001055
doi: 10.1097/MPA.0000000000001055
pubmed: 29683976
Zhang Y, Cheng H, Li W et al (2019) Highly-expressed P2X7 receptor promotes growth and metastasis of human HOS/MNNG osteosarcoma cells via PI3K/Akt/GSK3β/β-catenin and mTOR/HIF1α/VEGF signaling. Int J Cancer 145:1068–1082. https://doi.org/10.1002/IJC.32207
doi: 10.1002/IJC.32207
pubmed: 30761524
pmcid: 6618011
Vázquez-Cuevas FG, Cruz-Rico A, Garay E et al (2013) Differential expression of the P2X7 receptor in ovarian surface epithelium during the oestrous cycle in the mouse. Reprod Fertil Dev 25:971–984. https://doi.org/10.1071/RD12196
doi: 10.1071/RD12196
Zhang W jun, Luo C, Huang C et al (2021) PI3K/Akt/GSK-3β signal pathway is involved in P2X7 receptor-induced proliferation and EMT of colorectal cancer cells. Eur J Pharmacol 899. https://doi.org/10.1016/J.EJPHAR.2021.174041
Ulrich H, Ratajczak MZ, Schneider G et al (2018) Kinin and purine signaling contributes to neuroblastoma metastasis. Front Pharmacol 9. https://doi.org/10.3389/FPHAR.2018.00500
Arnaud-Sampaio VF, Rabelo ILA, Ulrich H, Lameu C (2020) The P2X7 receptor in the maintenance of cancer stem cells, chemoresistance and metastasis. Stem Cell Rev Rep 16:288–300. https://doi.org/10.1007/s12015-019-09936-w
doi: 10.1007/s12015-019-09936-w
pubmed: 31813120
Giannuzzo A, Pedersen SF, Novak I (2015) The P2X7 receptor regulates cell survival, migration and invasion of pancreatic ductal adenocarcinoma cells. Mol Cancer 14. https://doi.org/10.1186/S12943-015-0472-4
Dong C, Hu D, Liu S et al (2022) AKT/GSK-3beta/VEGF signaling is involved in P2RY2 activation-induced the proliferation and metastasis of gastric cancer. Carcinogenesis. https://doi.org/10.1093/CARCIN/BGAC095
doi: 10.1093/CARCIN/BGAC095
pubmed: 35084494
Zhou Q, Liu S, Kou Y et al (2022) ATP promotes oral squamous cell carcinoma cell invasion and migration by activating the PI3K/AKT pathway via the P2Y2-Src-EGFR axis. ACS Omega 7:39760–39771. https://doi.org/10.1021/ACSOMEGA.2C03727
doi: 10.1021/ACSOMEGA.2C03727
pubmed: 36385800
pmcid: 9648055
Zaparte A, Cappellari AR, Brandão CA et al (2021) P2Y2 receptor activation promotes esophageal cancer cells proliferation via ERK1/2 pathway. Eur J Pharmacol 891. https://doi.org/10.1016/J.EJPHAR.2020.173687
Eun SY, Ko YS, Park SW et al (2015) P2Y2 nucleotide receptor-mediated extracellular signal-regulated kinases and protein kinase C activation induces the invasion of highly metastatic breast cancer cells. Oncol Rep 34:195–202. https://doi.org/10.3892/OR.2015.3972
doi: 10.3892/OR.2015.3972
pubmed: 26063340
Buzzi N, Bilbao PS, Boland R, de Boland AR (2009) Extracellular ATP activates MAP kinase cascades through a P2Y purinergic receptor in the human intestinal Caco-2 cell line. Biochim Biophys Acta 1790:1651–1659. https://doi.org/10.1016/J.BBAGEN.2009.10.005
doi: 10.1016/J.BBAGEN.2009.10.005
pubmed: 19836435
Wang T, Takikawa Y, Watanabe A et al (2014) Proliferation of mouse liver stem/progenitor cells induced by plasma from patients with acute liver failure is modulated by P2Y2 receptor-mediated JNK activation. J Gastroenterol 49:1557–1566. https://doi.org/10.1007/S00535-013-0927-6
doi: 10.1007/S00535-013-0927-6
pubmed: 24362969
Ito N, Ruegg UT, Takeda S (2018) ATP-induced increase in intracellular calcium levels and subsequent activation of mTOR as regulators of skeletal muscle hypertrophy. Int J Mol Sci 19. https://doi.org/10.3390/IJMS19092804
Schäfer R, Sedehizade F, Welte T, Reiser G (2003) ATP- and UTP-activated P2Y receptors differently regulate proliferation of human lung epithelial tumor cells. Am J Physiol Lung Cell Mol Physiol 285. https://doi.org/10.1152/AJPLUNG.00447.2002
Chadet S, Jelassi B, Wannous R et al (2014) The activation of P2Y2 receptors increases MCF-7 breast cancer cells migration through the MEK-ERK1/2 signalling pathway. Carcinogenesis 35:1238–1247. https://doi.org/10.1093/carcin/bgt493
doi: 10.1093/carcin/bgt493
pubmed: 24390819
Choi KC, Tai CJ, Tzeng CR et al (2003) Adenosine triphosphate activates mitogen-activated protein kinase in pre-neoplastic and neoplastic ovarian surface epithelial cells. Biol Reprod 68:309–315. https://doi.org/10.1095/BIOLREPROD.102.006551
doi: 10.1095/BIOLREPROD.102.006551
pubmed: 12493727
Muscella A, Elia MG, Greco S et al (2003) Activation of P2Y2 receptor induces c-FOS protein through a pathway involving mitogen-activated protein kinases and phosphoinositide 3-kinases in HeLa cells. J Cell Physiol 195:234–240. https://doi.org/10.1002/JCP.10242
doi: 10.1002/JCP.10242
Xie R, Xu J, Wen G et al (2014) The P2Y2 nucleotide receptor mediates the proliferation and migration of human hepatocellular carcinoma cells induced by ATP. J Biol Chem 289:19137–19149. https://doi.org/10.1074/JBC.M113.540047
doi: 10.1074/JBC.M113.540047
pubmed: 24847054
pmcid: 4081950
Hevia MJ, Castro P, Pinto K et al (2019) Differential effects of purinergic signaling in gastric cancer-derived cells through P2Y and P2X receptors. Front Pharmacol 10. https://doi.org/10.3389/FPHAR.2019.00612
Cao Y, Wang X, Li Y et al (2019) Extracellular and macropinocytosis internalized ATP work together to induce epithelial-mesenchymal transition and other early metastatic activities in lung cancer. Cancer Cell Int 19. https://doi.org/10.1186/S12935-019-0973-0
Tafani M, Schito L, Pellegrini L et al (2011) Hypoxia-increased RAGE and P2X7R expression regulates tumor cell invasion through phosphorylation of Erk1/2 and Akt and nuclear translocation of NF-κB. Carcinogenesis 32:1167–1175. https://doi.org/10.1093/carcin/bgr101
doi: 10.1093/carcin/bgr101
pubmed: 21642357
Xia J, Yu X, Tang L et al (2015) P2X7 receptor stimulates breast cancer cell invasion and migration via the AKT pathway. Oncol Rep 34:103–110. https://doi.org/10.3892/OR.2015.3979
doi: 10.3892/OR.2015.3979
pubmed: 25976617
Li WH, Qiu Y, Zhang HQ, et al (2015) P2Y2 Receptor and EGFR cooperate to promote prostate cancer cell invasion via ERK1/2 pathway. PLoS One 10:. https://doi.org/10.1371/JOURNAL.PONE.0133165
Zhang JL, Liu Y, Yang H et al (2017) ATP-P2Y2-β-catenin axis promotes cell invasion in breast cancer cells. Cancer Sci 108:1318–1327. https://doi.org/10.1111/CAS.13273
doi: 10.1111/CAS.13273
pubmed: 28474758
pmcid: 5497932
Li WH, Qiu Y, Zhang HQ et al (2013) P2Y2 receptor promotes cell invasion and metastasis in prostate cancer cells. Br J Cancer 109:1666–1675. https://doi.org/10.1038/BJC.2013.484
doi: 10.1038/BJC.2013.484
pubmed: 23969730
pmcid: 3776994
Martínez-Ramírez AS, Garay E, García-Carrancá A, Vázquez-Cuevas FG (2016) The P2RY2 receptor induces carcinoma cell migration and EMT through cross-talk with epidermal growth factor receptor. J Cell Biochem 117:1016–1026. https://doi.org/10.1002/JCB.25390
doi: 10.1002/JCB.25390
pubmed: 26443721
Reyna-Jeldes M, De la Fuente-Ortega E, Cerda D et al (2021) Purinergic P2Y2 and P2X4 receptors are involved in the epithelial-mesenchymal transition and metastatic potential of gastric cancer derived cell lines. Pharmaceutics 13. https://doi.org/10.3390/PHARMACEUTICS13081234
Choi JH, Ji YG, Lee DH (2013) Uridine triphosphate increases proliferation of human cancerous pancreatic duct epithelial cells by activating P2Y2 receptor. Pancreas 42:680–686. https://doi.org/10.1097/MPA.0B013E318271BB4B
doi: 10.1097/MPA.0B013E318271BB4B
pubmed: 23462325
Gaggianesi M, Di Franco S, Pantina VD et al (2021) Messing up the cancer stem cell chemoresistance mechanisms supported by tumor microenvironment. Front Oncol 11. https://doi.org/10.3389/FONC.2021.702642
Bao S, Wu Q, McLendon RE et al (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444:756–760. https://doi.org/10.1038/NATURE05236
doi: 10.1038/NATURE05236
pubmed: 17051156
Diehn M, Cho RW, Lobo NA et al (2009) Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458:780–783. https://doi.org/10.1038/NATURE07733
doi: 10.1038/NATURE07733
pubmed: 19194462
pmcid: 2778612
Shiozawa Y, Nie B, Pienta KJ et al (2013) Cancer stem cells and their role in metastasis. Pharmacol Ther 138:285–293. https://doi.org/10.1016/J.PHARMTHERA.2013.01.014
doi: 10.1016/J.PHARMTHERA.2013.01.014
pubmed: 23384596
pmcid: 3602306
Daniele S, Zappelli E, Natali L et al (2014) Modulation of A1 and A2B adenosine receptor activity: a new strategy to sensitise glioblastoma stem cells to chemotherapy. Cell Death Dis 5. https://doi.org/10.1038/CDDIS.2014.487
Liu G, Yang S, Liu Y et al (2022) The adenosine-A2a receptor regulates the radioresistance of gastric cancer via PI3K-AKT-mTOR pathway. Int J Clin Oncol 27:911–920. https://doi.org/10.1007/S10147-022-02123-X
doi: 10.1007/S10147-022-02123-X
pubmed: 35122587
Rocha JD, Uribe D, Delgado J et al (2022) A2B adenosine receptor enhances chemoresistance of glioblastoma stem-like cells under hypoxia: new insights into MRP3 transporter Function. Int J Mol Sci 23. https://doi.org/10.3390/IJMS23169022
Jafari SM, Joshaghani HR, Panjehpour M, Aghaei M (2018) A2B adenosine receptor agonist induces cell cycle arrest and apoptosis in breast cancer stem cells via ERK1/2 phosphorylation. Cell Oncol 41:61–72. https://doi.org/10.1007/s13402-017-0359-z
doi: 10.1007/s13402-017-0359-z
Liu TZ, Wang X, Bai YF et al (2014) The HIF-2alpha dependent induction of PAP and adenosine synthesis regulates glioblastoma stem cell function through the A2B adenosine receptor. Int J Biochem Cell Biol 49:8–16. https://doi.org/10.1016/J.BIOCEL.2014.01.007
doi: 10.1016/J.BIOCEL.2014.01.007
pubmed: 24434023
Lan J, Lu H, Samanta D et al (2018) Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment. Proc Natl Acad Sci U S A 115:E9640–E9648. https://doi.org/10.1073/pnas.1809695115
doi: 10.1073/pnas.1809695115
pubmed: 30242135
pmcid: 6187157
Lan J, Wei G, Liu J et al (2022) Chemotherapy-induced adenosine A2B receptor expression mediates epigenetic regulation of pluripotency factors and promotes breast cancer stemness. Theranostics 12:2598–2612. https://doi.org/10.7150/THNO.70581
doi: 10.7150/THNO.70581
pubmed: 35401817
pmcid: 8965495
García-Rocha R, Monroy-García A, Hernández-Montes J et al (2019) Cervical cancer cells produce TGF-β1 through the CD73-adenosine pathway and maintain CD73 expression through the autocrine activity of TGF-β1. Cytokine 118:71–79. https://doi.org/10.1016/J.CYTO.2018.09.018
doi: 10.1016/J.CYTO.2018.09.018
pubmed: 30301599
García-Rocha R, Monroy-García A, Carrera-Martínez M et al (2022) Evidence that cervical cancer cells cultured as tumorspheres maintain high CD73 expression and increase their protumor characteristics through TGF-β production. Cell Biochem Funct 40:760–772. https://doi.org/10.1002/CBF.3742
doi: 10.1002/CBF.3742
pubmed: 36070413
pmcid: 9825969
Bertolini G, Compagno M, Belisario DC et al (2022) CD73/adenosine pathway involvement in the interaction of non-small cell lung cancer stem cells and bone cells in the pre-metastatic niche. Int J Mol Sci 23. https://doi.org/10.3390/IJMS23095126
Cao L, Bridle KR, Shrestha R et al (2022) CD73 and PD-L1 as potential therapeutic targets in gallbladder cancer. Int J Mol Sci 23. https://doi.org/10.3390/IJMS23031565
Hallaj S, Heydarzadeh Asl S, Alian F et al (2020) Inhibition of CD73 using folate targeted nanoparticles carrying anti-CD73 siRNA potentiates anticancer efficacy of Dinaciclib. Life Sci 259. https://doi.org/10.1016/J.LFS.2020.118150
Azambuja JH, Schuh RS, Michels LR et al (2020) CD73 as a target to improve temozolomide chemotherapy effect in glioblastoma preclinical model. Cancer Chemother Pharmacol 85:1177–1182. https://doi.org/10.1007/S00280-020-04077-1
doi: 10.1007/S00280-020-04077-1
pubmed: 32417936
Jain D, Somasundaram DB, Aravindan S et al (2021) Prognostic significance of NT5E/CD73 in neuroblastoma and its function in CSC stemness maintenance. Cell Biol Toxicol. https://doi.org/10.1007/S10565-021-09658-1
doi: 10.1007/S10565-021-09658-1
pubmed: 34773529
Ziberi S, Zuccarini M, Carluccio M et al (2019) Upregulation of epithelial-to-mesenchymal transition markers and P2X7 receptors is associated to increased invasiveness caused by P2X7 receptor stimulation in human glioblastoma stem cells. Cells 9. https://doi.org/10.3390/CELLS9010085
He X, Wan J, Yang X et al (2021) Bone marrow niche ATP levels determine leukemia-initiating cell activity via P2X7 in leukemic models. J Clin Invest 131. https://doi.org/10.1172/JCI140242
Kwak SH, Shin S, Lee JH et al (2018) Synthesis and structure-activity relationships of quinolinone and quinoline-based P2X7 receptor antagonists and their anti-sphere formation activities in glioblastoma cells. Eur J Med Chem 151:462–481. https://doi.org/10.1016/J.EJMECH.2018.03.023
doi: 10.1016/J.EJMECH.2018.03.023
pubmed: 29649742
Kim DC, Jin H, Lee JS et al (2020) P2Y2R has a significant correlation with Notch-4 in patients with breast cancer. Oncol Lett 20:647–654. https://doi.org/10.3892/OL.2020.11630
doi: 10.3892/OL.2020.11630
pubmed: 32565989
pmcid: 7286009
Cavaliere F, Nestola V, Amadio S et al (2005) The metabotropic P2Y4 receptor participates in the commitment to differentiation and cell death of human neuroblastoma SH-SY5Y cells. Neurobiol Dis 18:100–109. https://doi.org/10.1016/J.NBD.2004.09.001
doi: 10.1016/J.NBD.2004.09.001
pubmed: 15649700
Salvestrini V, Orecchioni S, Talarico G et al (2017) Extracellular ATP induces apoptosis through P2X7R activation in acute myeloid leukemia cells but not in normal hematopoietic stem cells. Oncotarget 8:5895–5908. https://doi.org/10.18632/ONCOTARGET.13927
doi: 10.18632/ONCOTARGET.13927
pubmed: 27980223
D’Alimonte I, Nargi E, Zuccarini M et al (2015) Potentiation of temozolomide antitumor effect by purine receptor ligands able to restrain the in vitro growth of human glioblastoma stem cells. Purinergic Signal 11:331–346. https://doi.org/10.1007/S11302-015-9454-7
doi: 10.1007/S11302-015-9454-7
pubmed: 25976165
pmcid: 4529851
Filippin KJ, de Souza KFS, de Araujo Júnior RT et al (2020) Involvement of P2 receptors in hematopoiesis and hematopoietic disorders, and as pharmacological targets. Purinergic Signal 16. https://doi.org/10.1007/S11302-019-09684-Z
Lemoli RM, Ferrari D, Fogli M et al (2004) Extracellular nucleotides are potent stimulators of human hematopoietic stem cells in vitro and in vivo. Blood 104:1662–1670. https://doi.org/10.1182/BLOOD-2004-03-0834
doi: 10.1182/BLOOD-2004-03-0834
pubmed: 15161674
Barbosa CMV, Leon CMMP, Nogueira-Pedro A et al (2011) Differentiation of hematopoietic stem cell and myeloid populations by ATP is modulated by cytokines. Cell Death Dis 2. https://doi.org/10.1038/CDDIS.2011.49
Ledur PF, Villodre ES, Paulus R et al (2012) Extracellular ATP reduces tumor sphere growth and cancer stem cell population in glioblastoma cells. Purinergic Signal 8:39–48. https://doi.org/10.1007/s11302-011-9252-9
doi: 10.1007/s11302-011-9252-9
pubmed: 21818572
Scheffel TB, Rockenbach L, Cruz FF et al (2022) Inhibition of ATP hydrolysis as a key regulator of temozolomide resistance and migratory phenotype of glioblastoma cells. Biochem Biophys Res Commun 601:24–30. https://doi.org/10.1016/J.BBRC.2022.02.062
doi: 10.1016/J.BBRC.2022.02.062
pubmed: 35220010
Ma XL, Hu B, Tang WG et al (2020) CD73 sustained cancer-stem-cell traits by promoting SOX9 expression and stability in hepatocellular carcinoma. J Hematol Oncol 13. https://doi.org/10.1186/S13045-020-0845-Z
Song L, Ye W, Cui Y et al (2017) Ecto-5’-nucleotidase (CD73) is a biomarker for clear cell renal carcinoma stem-like cells. Oncotarget 8:31977–31992. https://doi.org/10.18632/ONCOTARGET.16667
doi: 10.18632/ONCOTARGET.16667
pubmed: 28404888
pmcid: 5458263
Lupia M, Angiolini F, Bertalot G et al (2018) CD73 Regulates stemness and epithelial-mesenchymal transition in ovarian cancer-initiating cells. Stem Cell Rep 10:1412–1425. https://doi.org/10.1016/j.stemcr.2018.02.009
doi: 10.1016/j.stemcr.2018.02.009
Hajizadeh F, Moghadaszadeh Ardebili S, Baghi Moornani M et al (2020) Silencing of HIF-1α/CD73 axis by siRNA-loaded TAT-chitosan-spion nanoparticles robustly blocks cancer cell progression. Eur J Pharmacol 882. https://doi.org/10.1016/J.EJPHAR.2020.173235
Torres Á, Erices JI, Sanchez F et al (2019) Extracellular adenosine promotes cell migration/invasion of glioblastoma stem-like cells through A3 adenosine receptor activation under hypoxia. Cancer Lett 446:112–122. https://doi.org/10.1016/J.CANLET.2019.01.004
doi: 10.1016/J.CANLET.2019.01.004
pubmed: 30660649
Erices JI, Niechi I, Uribe-Ojeda A et al (2022) The low affinity A2B adenosine receptor enhances migratory and invasive capacity in vitro and angiogenesis in vivo of glioblastoma stem-like cells. Front Oncol 12. https://doi.org/10.3389/FONC.2022.969993
Glaser T, Cappellari AR, Pillat MM et al (2012) Perspectives of purinergic signaling in stem cell differentiation and tissue regeneration. Purinergic Signal 8:523–537. https://doi.org/10.1007/S11302-011-9282-3
doi: 10.1007/S11302-011-9282-3
pubmed: 22143354
Glaser T, De Oliveira SLB, Cheffer A et al (2014) Modulation of mouse embryonic stem cell proliferation and neural differentiation by the P2X7 receptor. PLoS One 9. https://doi.org/10.1371/JOURNAL.PONE.0096281
Arnaud-Sampaio VF, Bento CA, Glaser T et al (2022) P2X7 receptor isoform B is a key drug resistance mediator for neuroblastoma. Front Oncol 12. https://doi.org/10.3389/FONC.2022.966404
Rabelo ILA, Arnaud-Sampaio VF, Adinolfi E et al (2021) Cancer metabostemness and metabolic reprogramming via P2X7 receptor. Cells 10. https://doi.org/10.3390/CELLS10071782
Mani SA, Guo W, Liao MJ et al (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133:704–715. https://doi.org/10.1016/J.CELL.2008.03.027
doi: 10.1016/J.CELL.2008.03.027
pubmed: 18485877
pmcid: 2728032
Nguyen AM, Zhou J, Sicairos B et al (2020) Upregulation of CD73 confers acquired radioresistance and is required for maintaining irradiation-selected pancreatic cancer cells in a mesenchymal state. Mol Cell Proteomics 19:375–389. https://doi.org/10.1074/MCP.RA119.001779
doi: 10.1074/MCP.RA119.001779
pubmed: 31879272